Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
- A8650 SaxagliptinTarget: DPP-4Summary: Selective DPP4 inhibitor
- B5780 UAMC 00039 dihydrochlorideTarget: Dipeptidyl-peptidase IISummary: dipeptidyl peptidase II (DPP-II) inhibitor
- A8190 Semagacestat (LY450139)Summary: γ-secretase inhibitor
- A4077 BIBR 953 (Dabigatran, Pradaxa)Summary: Thrombin inhibitor,potent,reversible and direct
- A2585 MG-13226 CitationTarget: ProteasomeSummary: Proteasome inhibitor, Cell permeable, reversible
- A4050 GM 60012 CitationTarget: MMPSummary: Broad spectrum MMP inhibitor
- A3690 OtamixabanTarget: Factor XaSummary: Direct factor Xa inhibitors,potent and selective